Recent Updates
Recently added Catalysts

CTLA4Ig/ Abatacept

Phase 2

Psoriasis Vulgaris | Small molecule | Dermatology |Bristol-Myers Squibb Company|Last Updated: Apr 25, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment144

FDA Designations

No designations recorded

Clinical trial landscape

CTLA4Ig/ Abatacept · 1 trial · 1 indication

Phase 2 1
NCT00287547Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisPsoriasis Vulgaris
COMPLETED144 Analytics
PHASE2COMPLETED
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Psoriasis Vulgaris
NCT00287547144
Unlock trial analytics

Study Endpoints

Primary Endpoints

Using the Psoriasis Disablity Index (PDI) and other assessment tools to determine if the patient's psoriasis improved or worsened over the course of the study.

Secondary Endpoints

Safety and immunogenicity; pharmacodynamic and PK; Percent reduction in PASI, PASI component scores and Total Body Surface Area; Clinical response kinetics; clinical relapse kinetics; physician global assessment; psoriasis disability index.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
CTLA4Ig / AbataceptDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Diagnosis and documentation of a history of stable psoriasis vulgaris of at least 6 months duration. * vulgaris total body surfae area involvement of at least 10% * Failure for toxicity and/or inefficacy of at least one standard anti- psoriatic therapy including topical treatm...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about CTLA4Ig/ Abatacept

What is CTLA4Ig/Abatacept used for in Psoriasis Vulgaris?

CTLA4Ig/Abatacept is an investigational drug being studied for the treatment of Psoriasis Vulgaris. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 2 clinical development. The drug has completed one clinical trial for this condition.

What does CTLA4Ig/Abatacept target?

CTLA4Ig/Abatacept is a small molecule that targets CTLA4, a protein involved in immune response regulation. By modulating this target, the drug aims to affect the immune pathways implicated in Psoriasis Vulgaris. This mechanism is being evaluated in clinical trials for its potential therapeutic effect.

Who makes CTLA4Ig/Abatacept?

CTLA4Ig/Abatacept is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the stock exchange under the ticker BMY. The company is conducting clinical research on this drug for the treatment of Psoriasis Vulgaris.

What phase is CTLA4Ig/Abatacept in?

CTLA4Ig/Abatacept is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy for the treatment of Psoriasis Vulgaris.

What clinical trials is CTLA4Ig/Abatacept in?

CTLA4Ig/Abatacept has one completed clinical trial, identified by the National Clinical Trial number NCT00287547. This was a Phase II randomized, double-blind, placebo-controlled study involving 144 patients with Psoriasis Vulgaris, conducted in the United States.

Is CTLA4Ig/Abatacept the same as Abatacept?

Yes, CTLA4Ig/Abatacept is also known as Abatacept. The drug is referred to by both names in clinical research. It is being studied under the name CTLA4Ig/Abatacept in the context of the Phase 2 trial for Psoriasis Vulgaris.